首页> 美国卫生研究院文献>Tropical Medicine and Health >Evaluation of the Safety and Adverse Effects of Goreisan/Wulingsan a Traditional Japanese-Chinese Herbal Formulation (Kampo) in a Rat Model: a Toxicological Evaluation
【2h】

Evaluation of the Safety and Adverse Effects of Goreisan/Wulingsan a Traditional Japanese-Chinese Herbal Formulation (Kampo) in a Rat Model: a Toxicological Evaluation

机译:在大鼠模型中评估传统日本中草药制剂(坎波)Goreisan / Wulingsan的安全性和不良反应:毒理学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diarrhea is the second leading cause of death among children less than 5 years of age. Most of these deaths occur in developing countries in the tropical areas of Africa and South Asia. Goreisan/Wulingsan, a formula of Japanese-Chinese medicinal herbs (Kampo), has been used for the treatment of diarrhea and vomiting from ancient times in East Asia. Therefore, we planned a randomized controlled clinical trial of Goreisan/Wulingsan in Bangladeshi children. Although it is believed to be safe in East Asia, information regarding its toxicity on animals is scarce. Since Goreisan/Wulingsan has never been used in Bangladesh, it was necessary to ensure the safety of the formula in an animal experiment. Rats were assigned to a control group (normal saline, n = 4) or various Goreisan/Wulingsan groups (n = 26) receiving doses of 1 to 8 mg/g/day (7.7 to 61.5 times the recommended pediatric dose) over a period of 25 days. Their activities and health conditions were observed until they were sacrificed, after which blood samples were collected for biochemical liver function tests. The kidneys, liver and heart tissue were collected for histopathological study. No lethality was observed during the experiment. All of the rats consumed the doses completely and no constipation was observed, suggesting the absence of any inhibitory effect on intestinal motion. Also, no abnormal neurological activity was detected, nor any significant elevation of AST, ALT or ALP levels, except for AST and ALT at the highest dose of 8 mg/g/day. Histopathological studies of the kidneys, liver and heart tissues revealed no abnormalities.In conclusion, our results showed that Goreisan/Wulingsan is safe for rats, thereby justifying the use of the drug in a human trial.
机译:腹泻是5岁以下儿童中第二大死亡原因。这些死亡大多数发生在非洲和南亚热带地区的发展中国家。 Goreisan / Wulingsan是日中草药(Kampo)的配方,已被用于治疗东亚古代的腹泻和呕吐。因此,我们计划在孟加拉国儿童中对Goreisan / Wulingsan进行随机对照临床试验。尽管人们认为它在东亚是安全的,但有关其对动物毒性的信息却很少。由于Goreisan / Wulingsan从未在孟加拉国使用过,因此有必要在动物实验中确保配方的安全性。将大鼠分为对照组(生理盐水,n = 4)或各种戈瑞森/雾灵山组(n = 26),在一段时间内接受1至8 mg / g / g /天的剂量(建议的儿科剂量的7.7至61.5倍) 25天。观察其活动和健康状况,直至处死,然后收集血样进行生化肝功能测试。收集肾脏,肝脏和心脏组织用于组织病理学研究。实验期间未观察到致死性。所有大鼠都完全消耗了剂量,没有观察到便秘,表明对肠运动没有任何抑制作用。此外,除了最高剂量为8 mg / g / day的AST和ALT之外,未检测到异常的神经活动,也没有任何AST,ALT或ALP的明显升高。对肾脏,肝脏和心脏组织的组织病理学研究未发现异常。总而言之,我们的结果表明,Goreisan / Wulingsan对大鼠是安全的,从而证明该药物在人体试验中的使用是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号